TELA Bio

TELA

Market cap $51.2M

MALVERN, Pa., Nov. 19, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler's 37th Annual Healthcare Conference.

MALVERN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of (i) restricted stock units covering 30,200 shares of its common stock to seventeen newly-hired employees and (ii) an option to purchase 25,000 shares of its common stock to one employee, with a grant date of November 10, 2025 (the "Grant Date"). The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.

TELA Bio Inc (NASDAQ: TELA) reported mixed results for the third quarter on Thursday.

TELA Bio, Inc. ( TELA ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Antony Koblish - Co-founder, CEO & Director Jeffrey Blizard - President of TELA Bio & Director Roberto Cuca - CFO & COO Jim Hagen Conference Call Participants Louisa Smith - Gilmartin Group LLC Caitlin Cronin - Canaccord Genuity Corp., Research Division Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Michael Sarcone - Jefferies LLC, Research Division Samantha Munoz Presentation Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.

TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.42 per share a year ago.

MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the pricing of an underwritten registered direct offering of 4,189,000 shares of its common stock at a price of $1.11 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 7,523,000 shares of common stock at an offering price of $1.1099 per pre-funded warrant, which represents the per share offering price for the shares of common stock less the $0.0001 per share exercise price. The gross proceeds to TELA from the offering, before deducting underwriting discounts and estimated offering expenses, are expected to be approximately $13.0 million, assuming no exercise of the pre-funded warrants. The offering is expected to close on or about November 17, 2025, subject to the satisfaction of customary closing conditions.

MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the third quarter ended September 30, 2025.

MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Betty Jo Rocchio, DNP, RN, CRNA, CENP, EBP-C, to its Board of Directors, and the departure of Lisa Colleran, who has stepped down following five years of service on the Board.

TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.51 per share a year ago.

TELA Bio, Inc. (NASDAQ:TELA ) Q2 2025 Earnings Conference Call August 11, 2025 4:30 PM ET Company Participants Antony Koblish - Co-founder, CEO & Director Jeffrey Blizard - President of TELA Bio & Director Roberto E. Cuca - CFO & COO Conference Call Participants Caitlin Cronin - Canaccord Genuity Corp., Research Division Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division Michael Anthony Sarcone - Jefferies LLC, Research Division Louisa Smith - Gilmartin Group LLC Operator Thank you for standing by, and welcome to TELA Bio's Second Quarter 2025 Earnings Conference Call.